Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis

• Published in: Blood Vol. 134; no. Supplement_1; p. 671
• Main Authors: Harrison, Claire N, Garcia, Jacqueline S, Mesa, Ruben A, Somervaille, Tim CP, Komrokji, Rami S., Pemmaraju, Naveen, Jamieson, Catriona, Papadantonakis, Nikolaos, Foran, James M., O'Connell, Casey L., Holes, Leanne, Jia, Jia, Harb, Jason, Hutti, Jessica, Prchal, Josef T.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 13.11.2019

Background: Myelofibrosis (MF) is associated with bone marrow fibrosis (BMF), splenomegaly, a high symptom burden, and poor prognosis; the JAK/STAT pathway is the central pathway implicated in its pathogenesis. Ruxolitinib, a JAK1/2 inhibitor and the only FDA-approved pharmacotherapy for treatment (...